# Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Source: https://onco.cc/trials/nct06567743/  
OnCo record `nct06567743` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by CG Oncology, Inc., now recruiting.

## Summary

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC is a phase 2 interventional study registered as NCT06567743 by CG Oncology, Inc., with 325 participants planned, started 2024-09-16 and due to reach its primary completion in 2027-03-31. Interventions recorded: Cretostimogene Grenadenorepvec.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06567743
- Phase: 2
- Setting: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Sponsor: CG Oncology, Inc.
- Enrolled: 325

## Sources

- ClinicalTrials.gov NCT06567743: https://clinicaltrials.gov/study/NCT06567743

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Cretostimogene grenadenorepvec](https://onco.cc/drugs/cretostimogene/)

---
JSON: https://onco.cc/api/v1/entities/nct06567743.json